In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Value of lung ultrasound in chronic stable ambulatory heart failure patients

Session Poster Session 2

Speaker Evelyn Santiago Vacas

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure – Epidemiology, Prognosis, Outcome
  • Session type : Poster Session

Authors : M Domingo (Barcelona,ES), L Conangla (Barcelona,ES), J Lupon (Barcelona,ES), M De Antonio (Barcelona,ES), P Moliner (Barcelona,ES), E Santiago-Vacas (Barcelona,ES), E Zamora (Barcelona,ES), B Gonzalez (Barcelona,ES), V Diaz (Barcelona,ES), C Rivas (Barcelona,ES), P Velayos (Barcelona,ES), J Santesmases (Barcelona,ES), S Altimir (Barcelona,ES), M Boldo (Barcelona,ES), A Bayes-Genis (Barcelona,ES)

M Domingo1 , L Conangla1 , J Lupon1 , M De Antonio1 , P Moliner1 , E Santiago-Vacas1 , E Zamora1 , B Gonzalez1 , V Diaz1 , C Rivas1 , P Velayos1 , J Santesmases1 , S Altimir1 , M Boldo1 , A Bayes-Genis1 , 1Germans Trias i Pujol University Hospital - Badalona (Barcelona) - Spain ,


Background: The role of lung ultrasound (LUS) in diagnosis and response to diuretic treatment of patients with acute HF has been widely studied, but less is known about its value in chronic HF.

Purpose: To assess the prognostic value of LUS in a cohort of chronic HF stable ambulatory patients and to explore the relationship of LUS findings with clinical data, such as NYHA functional class, left ventricular ejection fraction (LVEF) and NTproBNP.

Methods: Consecutive stable ambulatory patients who attended a scheduled follow-up visit in a HF clinic were included. LUS were performed with a pocket device and examined 4 chest areas per side (two anterior and two lateral). Scans were analysed offline by two investigators blinded to clinical data, who evaluated the number of B-lines of each area. The addition number of B-lines of each area and the quartiles of such addition were used for the analyses. The primary outcome end-point was the composite of all-cause death or hospitalization due to HF at one year. Linear regression and Cox regression analyses were performed.

Results: Five-hundred seventy-seven patients were included between July 2016 and July 2017 (age 69 ± 12 years, 72% men). The main HF aetiology was ischemic heart disease (43%) followed by dilated cardiomyopathy (20%). Median HF duration was 79 months (Q1-Q3 38-144). Mean LVEF was 45%±13 (mean LVEF when admitted at the Unit 34%±13). Most patients were in NYHA functional class II (70%), 13% were in class I and 17% in class III. Median NTproBNP was 722 ng/L (Q1-Q3 262-1760). Mean number of B-lines  was 5 ± 6 (Q1, 0; Q2, 1-3; Q3, 4-7; Q4, =8).  The number of B-lines was associated with age (beta-coefficient 0.11, p<0.001), NYHA functional class (beta-coefficient 1.75, p<0.001), and logNTproBNP (beta-coefficient 1.40, p<0.001). Mean number of B-lines according to NYHA functional class was: class I, 3.5 ± 6; class II, 4.9 ± 6; and class III, 7.1 ± 7. During the one year follow-up 47 patients suffered the primary end-point. In total there were 24 HF related hospitalizations and 26 deaths. In Cox regression analysis, Q4 of B-lines showed a double risk of suffering the primary end-point (HR 2.13 [95%CI 1.18-3.84], p=0.01). However, statistically significance was not maintained for LUS results in the multivariable analysis when age, NYHA functional class and logNTproBNP were included in the model, although a 38% increase in the risk of suffering the primary end-point for Q4 was observed (HR 1.38 [95%CI 0.75-2.54], p=0.31).

Conclusion: In outpatients with stable chronic HF, the number of B-lines detected in LUS was associated with age, NYHA functional class and NTproBNP. Patients having =8 B-lines had a significant double risk of HF related hospitalization or all-cause death at one year. However, when strongly powerful prognostic variables such as NYHA class and NTproBNP were included in the model LUS did not retain an independent prognostic role.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are